| LTUS Stock | | | USD 0.0008 0 75.76% |
CFO
Ms. Zeng Yan is Chief Financial Officer of Lotus Pharmaceuticals Inc. She has over ten years experience as a financial manager and auditor for Chinese based companies. From September 3, 2010 to September 21, 2010, Ms. Zeng served as an accountant for Beijing Liang Fang Pharmaceutical Ltd.. From May 1, 2009 to September 2, 2010, Ms. Zeng served as Chief Financial Officer of Lotus Pharmaceuticals, Inc.. From 2008 to April 30, 2009, Ms. Zeng was an accountant for Beijing Liang Fang Pharmaceutical Ltd., a subsidiary of Lotus Pharmaceuticals, Inc.. From 2005 to 2008, Ms. Zeng was a registered accountant in Beijing Topson Certified Public Accountants, where she conducted auditing and provided financial counsel for public companies. From 2004 to 2005, Ms. Zeng was a financial manager for Beijing Unite Youbang Science and Technology Ltd since 2010.
| Age | 54 |
| Tenure | 14 years |
| Professional Marks | CPA |
| Phone | 615 310 2688 |
| Web | https://lotuspharmaceuticalsusa.com |
Zeng is a CPA in China with bachelor degree in Business from Beijing Information Science & Technology University.
Lotus Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.0182 %, meaning that it created $0.0182 on every $100 dollars invested by stockholders. Lotus Pharmaceuticals' management efficiency ratios could be used to measure how well Lotus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Lotus Pharmaceuticals currently holds 5.24
M in liabilities with Debt to Equity
(D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lotus Pharmaceuticals has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Lotus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lotus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lotus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lotus to invest in growth at high rates of return. When we think about Lotus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | CFO Age |
| Scott CPA | DiaMedica Therapeutics | 59 |
| Adam Levy | Mineralys Therapeutics, Common | 46 |
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the Peoples Republic of China. Lotus Pharmaceutical operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 233 people. Lotus Pharmaceuticals [LTUS] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Lotus Pharmaceuticals Management Team
Elected by the shareholders, the Lotus Pharmaceuticals' board of directors comprises two types of representatives: Lotus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lotus. The board's role is to monitor Lotus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lotus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lotus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Lotus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lotus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Lotus Pink Sheet Analysis
When running Lotus Pharmaceuticals' price analysis, check to
measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.